departure director

another indication of the profound strategic change taking place from last October to today.

James Anthony Bonner as director of clinical operations and regulatory affairs in force at Neuren since October 2006, on February 16th ended his relationship and moved to a new American biotech engaged in preclinical studies of neuroscience as vice president of research and development.

the guy spent almost 12 years in Neuren and it is not a trivial matter.
with the end of last year's release of Hancox and now Bonner it seems that the company has made radical choices in the last months. the feeling stronger and stronger is that the process is underway towards a merger with someone who has everything necessary to advance and manage the pre-commercial phases which are obviously the most expensive in the whole experimentation process and which Neuren is absolutely not able to face financially even with a massive ADC.
at this point, who has remained in Neuren as executive or non-executive directors, will be the holder of ordinary shares from 7 May; the only one excluded is Glass's deputy Doctor Nancy. also this aspect is significant in the hypothesis of a sale of the entire company which, by logic, is more interested in the direct interests than the retail.